Physician profile
Anthony Chidiac
NPI 1932162682
$3,461.25
in general payments reported to CMS, 2019-2025
26 companies · $948 in 2025
The $948 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $313 · 2022: $654 · 2023: $478 · 2024: $529 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794 · Education: $137 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.58 |
| Education | $137.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $363.45 | 2024 | |
| Csl Behring | $341.97 | 2020-2025 | Kcentra |
| Stryker Corporation | $327.34 | 2022-2025 | Spy-Phi System |
| Kerecis Limited | $250.00 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Pacira Pharmaceuticals Incorporated | $246.82 | 2020-2023 | Iovera |
| Innovation Technologies INC | $171.85 | 2025 | Irrisept |
| Atricure, INC. | $165.83 | 2024 | |
| Acumed LLC | $157.93 | 2023 | Ribloc |
| Tela Bio, INC. | $150.81 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $149.11 | 2023 | Caldolor |
| Baxter Healthcare | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Acell, INC. | $125.00 | 2019 | |
| Heron Therapeutics, INC. | $121.84 | 2025 | Aponvie, Zynrelef |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $118.24 | 2025 | Gattex |
| Medline Industries LP | $99.82 | 2019 | |
| Kci USA, INC. | $98.61 | 2022 | |
| Therapeuticsmd, INC. | $34.87 | 2019 | |
| Roche Diagnostics Corporation | $30.62 | 2019 | |
| Hologic Sales and Service, LLC | $29.53 | 2020 | |
| Davol INC. | $23.34 | 2023 | Phasix Mesh |
| Pfizer INC. | $22.70 | 2023 | |
| Lupin INC. | $20.60 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.80 | 2022 | |
| Abbvie INC. | $17.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Chidiac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.